Thoughts on corporate finance, personal finance, valuations and more
New Article: Don’t buy AXIM
I did some research on Axim Biotechnologies, and frankly, it’s terrible. In short, they received a patent that is next-to-worthless, and their value rose 25%, or about $87 million. Very disproportionate to the actual value of the underlying asset.